Get access to our best features

Get access to our best features

Published 2 years ago

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Summary by Ground News

Clearside Biomedical, Inc. has entered into a Royalty Interest Purchase and Sale Agreement (the agreement) with HealthCare Royalty Partners. Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline. The agreement includes customary provisions for a transaction of this nature. Bausch + Lomb, a leading global eye health company, has the exclusive license for the commercialization and development of XIPERE in the United States and Canada.

0 Articles

0 Articles

All

Left

Center

Right

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Transaction Supports Progression of CLS-AX Clinical Program -...

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated2 years agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.